To investigate the incidence proportion of obesity and its influencing factors in patients with schizophrenia (SCH).
Key Findings:
The incidence proportion of obesity in patients with SCH was 33.0%.
Significant risk factors for obesity included female sex (OR = 1.14, 95% CI = 1.10–1.20), elevated FG (OR = 1.08, 95% CI = 1.04–1.12), diabetes (OR = 2.36, 95% CI = 1.79–3.10), high TG levels (OR = 1.13, 95% CI = 1.08–1.18), elevated LDL (OR = 1.88, 95% CI = 1.45–2.44), and olanzapine use (OR = 7.40, 95% CI = 4.98–11.00).
Combined antipsychotic therapy (OR = 3.19, 95% CI = 2.31–4.41) and use of both typical (OR = 1.46, 95% CI = 1.18–1.82) and atypical antipsychotics (OR = 1.70, 95% CI = 1.42–2.03) were also associated with increased obesity risk.
Interpretation:
The findings highlight the need for early screening and targeted interventions to address obesity in patients with schizophrenia, improving their quality of life.
Limitations:
Heterogeneity and inconsistent findings across studies may limit the generalizability of the results.
Exclusion of non-original research publications and studies with unavailable full texts may introduce bias.
Conclusion:
Identifying and managing obesity risk factors in SCH patients is crucial for reducing complications and improving overall health outcomes.
A four-factor staging system stratified response rates from 90.9% to 37.5% in a retrospective cohort study, although the model showed only moderate discrimination (C statistic, 0.68) and requires external validation
